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Introduction 
Early weaning programs have been aimed 
at the control and elimination of respiratory 
infections in the young pig. Segregation from 
their dams at less than 21 .days, batch rearing 
with all-in all-out by room, building, or site, and 
proper biosecurity (cleaning, disinfecting and 
quarantine) are mandatory to implement early 
weaning programs 1. Early weaning with all its 
components gives a tremendous economic 
advantage to those who use this technology. 
This technology however does not come without 
a cost. This requires necessary building sites, 
scheduling and a high level of management. 
Enteric infections such as neonatal coccidiosis 
and post weaning diarrhea problems have not 
been prevented by early wean programs. 
Although the Pork Quality Assurance Program 
has been developed to achieve the highly 
desirable goal of reduced antibiotic use, there 
are feed and water medication is needed for 
prevention and control of enteric infections. 
We were interested in the effects of low 
levels of conventional water and feed grade 
antibiotic treatments on performance and 
immunological parameters of the young pig 
infected with the common enteric pathogens, E. 
coli and rotavirus. Previously, we had tested 
this treatment at both a research facility and a 
commercial operation and had shown increased 
production and decreased immunological 
response in the treated animals2·3• We have 
established that the use of such a program 
would be a benefit to those producers who do 
not have the production facilities that would 
allow early weaning (7-10 days) and/or multi-site 
production. However the effect of these oral 
treatments on minimizing production losses and 
activation of the immune system following 
1 Department of Veterinary Science 
2 Department of Animal and Range Sciences 
3 SDSU and Rural Technologies Inc., Brookings, SD 
4 American Cyanamid Company, Princeton, NJ 
130 
infection with enteric infections has not been 
established. 
The purpose of this study was to measure 
production and immunological parameters in 
orally medicated and control animals following a 
post weaning E. coli and rotavirus challenge. 
Experimental Procedure 
Animals and Management 
Farrowing and neonatal pig management: A 
commercial 130-head sow herd of known health 
status was chosen for this trial. This is a herd 
whose health status is monitored by Dr. Chase. 
The farrowing facility is a two-year-old building 
with 2-10 crate rooms. Pigs were processed at 
1 day of age (tails removed, iron dextran 
injections, needle teeth clipped). The pigs were 
vaccinated for Mycoplasma hyopneumoniae at 
7-11 days of age and the boars were castrated. 
Prior to vaccination on day 7-11, a 3 ml blood 
sample was collected. At day 17-21 (weaning 
day) the pigs were re vaccinated with M. 
hyopneumoniae and a 10 ml heparinized blood 
sample were collected from 10 pigs in each 
group. 
Ten sows (ten litters-92 pigs: 5 litters/group) 
were randomly assigned to one of two groups: 
1) control and 2) treatment. The treatment 
regimen consisted of feeding 400 g/ton of 
Aureomycin™ in the gestation-lactation ration 
for 1 week before and 1 week after farrowing. 
The baby pigs' water was treated with water 
soluble Aureomycin™ to deliver 1 O mg/# body 
weight beginning day 2 post farrowing through 
day 9 post farrowing. Auero-Sulmet™ soluble 
was added to the pigs' drinking water at rate of 
250 mg chlortetracycline/250 mg sulfamethazine 
per gallon from day 10 post farrowing through 
day 27-34 post farrowing (10 days 
postweaning). ASP250™ at a rate of 100 gm 
Chlortetracycline/100 gm sulfamethazine/50 gm 
penicillin per ton was used in the creep feed. 
Control pigs diets were managed using the 
farm's husbandry procedures and all control 
creep contained 40 grams/ton of Apralan ™. 
Nursery management: The pigs were 
weaned at 17-21 days of age and transported 
100 miles from Brookings, SD to Beresford, SD 
to an newly remodeled nursery-finisher isolation 
facility. The nursery facility contained 2 rooms 
each room contained 10-6' ft X 16' pens. The 46 
treatment and 46 control pigs were each divided 
into 8 replicates. Eight pens in one room were 
divided with plywood and plastic coated wire 
was placed over the slats to prevent injury to the 
young pigs. Treated pigs were placed in one 
half and control pigs were placed in the other 
half of each pen. The treated pigs received 
Auero-Sulmet™ soluble in the drinking water at 
rate of 250 mg chlortetracycline/250 mg 
sulfamethazine per gallon for 1 O days post 
weaning (day 27-34 post farrowing). All the pigs 
received traditional phase I, II, & Ill commercial 
nursery diets4• Diet changes were made at 7 
and 21 days post weaning. The treated pigs 
nursery diet contained ASP250™ at a rate of 
100 gm chlortetracycline/ 100 gm 
sulfamethazine/ 50 gm penicillin per ton. 
Control pigs weaning diets contained 40 
grams/ton of Apralan™. All pigs were switched 
to 20 grams/ton of Tylan 1 O for the 
grower/finisher phase and these diets were 
standard grow finish diets. The pigs were 
weighed weekly through day 160. All feed was 
weighed to obtain feed efficiency data. 
Microbiological challenge: Rotavirus (OSU 
strain) was obtained from Dr. David Benfield, 
Dept. Vet. Sci., South. Dakota State University 
(SDSU). The stock virus had been passed 
through pigs. The virus was grown on MA 104 
cells, harvested and titrated. The tier of the 
challenge virus was 6.25 X 109 TCID50. The 
virus was diluted with minimum essential media 
(MEM) to give each pig a 2 ml challenge dose of 
107 of TCID50 rotavirus p.o. The 0111 strain of 
E.coli was grown in broth cultures and diluted to 
250 ml with PBS and each pig was given a 2 ml 
dose p.o. that containing 108 E.coli 0111. The 
pigs were challenged 2 days after arriving at the 
nursery facility (19-23 days of age). 
Clinical indices: Clinical sign~ (fever and 
diarrhea) were recorded. The temperature of 
the same one or two pigs/pen was taken for 15 
days. Diarrhea was assessed daily in each pen 
on a scale of 0-4 (0-firm, formed feces; 1-pasty 
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feces; 2-pudding feces; 3-slightly runny feces; 
and 4-watery feces) for 29 days. 
Microbiological tests: A fecal sample was 
collected using a sterile swab from one pig in 
each pen on the day of challenge and 3, 10, 16, 
24, 28, and 35 days PC. 
Bacteriology: The swabs were streaked. by 
the SDSU Diagnostic Bacteriology Laboratory 
on .differential plates. The number of hemolytic 
E. coli was estimated. E.coli isolates were then 
typed for 0111. 
Virology: The fecal swabs were then pooled 
according to treatment groups and the samples 
examined with an electron microscope for the 
presence of rotavirus by the SDSU Electron 
Microscopy Laboratory. 
Serology: Blood was collected and serum 
samples were harvested at 7-11 and 53-57 days 
of age (35 days PC) from 1 O pigs in each group. 
Serum samples were tested for 
M. hyopneumoniae antibodies using as 
commercial M. hyopneumoniae ELISA 
performed by Oxford Diagnostic Laboratories, 
Worthington, MN. 
Clinica Jmmuno/ogy:1 O ml-heparinized blood 
was collected and lymphocytes harvested at 17-
21 (weaning day), 23-27 (4 days PC), 30-34 (11 
days PC) and 53-59 days of age (34 days PC) 
from 10 pigs in each group. Mitogen 
proliferation assays were conducted in the 
SDSU Clinical Immunology Laboratory. The 
plant lectins, concanavalin A (ConA) at 1 µg/ml, 
phytohemagglutinin A (PHA) at 1 µg/ml and 
pokeweed mitogen '(PWM) at 5 µg/ml were used 
to ·stimulate isolated peripheral blood 
lymphocytes. The lymphocytes were cultured 
for 44 hours and pulsed for 4 hours with tritiated 
(3H) thymidine and harvested at 48 hrs in a cell 
collector. The disks were counted in a liquid 
scintillation counter. All cultures were done in 
triplicate and the values represent the mean 
specific incorporation (sample m'ean-
unstimulated cell mean) of the triplicate 
samples. Forced antibody production was 
performed after the protocol of Hammerburg et. 
al5• Briefly, 1 ml of mononuclear cells at 3 X 
106/ml were incubated in 12 X 75 mm sterile 
plastic tubes containing 1 ml of RPMI with 
1 O µg/ml of PWM for 72 hours. The tubes were 
centrifuged and the supernatant was collected. 
The supernatant was diluted in a ten fold series 
and a polyclonal-polyclonal sandwich capture 
ELISA was used to measure the total amount of 
immunoglobulin present. The assay was 
standardized with a preparation of porcine lgG 
(Sigma, St. Louis, MO). 
Results 
Production Results from the growth trial are 
presented in Table 1•·•. In the starter phase, the 
treatment protocol improved daily gain (P<.124) 
and feed efficiency (P<0.079) (Table 1•). In the 
grower, finisher, and overall growth phases, 
performance was not affected by treatment 
(P>.10) (Tables 1•·d). Ultrasonic measurements 
of 10th rib backfat thickness and loin eye area at 
240 lbs. were unaffected by treatment (P>.10) 
(Table 1°). 
Clinical Signs: The temperatures of the 
treated pigs were not significantly different from 
the control group from day 1 to day 15 PC) 
(Figure 1 ). The temperatures of the treated pigs 
were in the normal range throughout the trial 
(Figure 1 ). From Day 6 to Day 15, the 
temperatures of the treated pigs were lower than 
the control. The diarrhea scores were similar 
between control and treatment groups. The 
diarrhea was biphasic in the control group at 4-5 
days PC and at 18-24 days PC. The highest 
amount of diarrhea occurred at Days 18-22 PC 
(Figure 2). 
Microbiology: No rotavirus was identified 
prior to challenge (Table 2). Rotavirus was 
identified at Day 3 PC in both control and treated 
pigs. Rotavirus was also identified at Day 10 
and Day 16 PC (Table 2) in the control pigs. 
Hemolytic E.coli was isolated from 1 treatment 
pen prior to beginning the study (Table 3). Tests 
are under way to determine the serotype. 
Hemolytic E.coli at moderate levels were 
isolated at Days 16 and 24 PC. No hemolytic 
E.coli was isolated from the control pigs prior to 
the study. Hemolytic E.coli was present in 
through out the trial in the control group 
(Table 3). Serotyping of the E.coli established 
that the challenge was 0111 but subsequent 
isolations throughout the trial were negative for 
0111. 
Serology: There was no serological 
response to the M. hyopneumoniae vaccination 
in the treated pigs and a very small response 
(1/10) of the control pigs (Table 4). Three of the 
control pigs had passive M. hyopneumoniae 
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titers and none of the treated pigs and passive 
titers (Table 4). 
Clinical immunology: T cell mitogen activity, 
B cell mitogen activity and induced 
immunoglobulin (lg) were measured in the 
treatment and control groups (Figures 3-5). The 
immunological response with the T cell mitogens 
with both phytohemagglutinin (PHA) and 
concanavalin A (ConA) was lower in the 
treatment group (Figure 3). The ConA response 
was significantly lower (P<0.05) at 17, 30 and 56 
days of age (Figure 3). The B and T cell 
mitogen pokeweed mitogen (PWM) (Figure 4) 
and the forced antibody production assays 
(Figure 5) had a different pattern from the T cell 
assays. Prior to challenge on day 17, B cell 
proliferation (Figure 4) and induced antibody 
production (Figure 5) were similar in both 
groups. At 23 days of age (4 days PC) both 
parameters were depressed. At 30 days of age, 
the B cell mitogen activity (Figure 4) and the 
induced antibody production (Figure 5) were 
higher in the treatment group. Al 56 days of 
age, the B cell mitogen activity was similar in 
both groups and the forced antibody production 
was higher in the control group. 
Discussion 
The production results indicate again an 
early advantage in rate of gain and feed 
efficiency in the treatment group (Table 1•). 
However by the end of the trial the two groups 
were similar in these parameters (Table 1'"). 
Data from this trial indicate that this MMEW 
protocol improves nursery performance but 
compensatory performance masks those 
benefits in the grower and finisher phases. 
These results may represent what would happen 
under field conditions following removal from 
water antibiotic therapy. One of the main design 
issues is that the control and treatment animals 
were housed in adjacent pens throughout the 
trial. The treated pigs could have become 
infected after the end of the treatment resulting 
in similar production results at the end of the 
study. In the future, strict segregation should be 
used to determine the long-term effect of this 
antibiotic therapy. 
Clinical scores were similar for both groups. 
The initial design called for monitoring 
temperatures for 14 days. The data indicates 
that temperatures were on the rise and with the 
occurrence of diarrhea at 18 days temperatures 
should be monitored concurrently with diarrhea. 
The diarrhea scores indicate that the treated 
pigs were partially protected from the initial 
diarrheal phase at 4-5 days PC. Duration and 
severity of the second phase was similar 
between the two groups. Again the 
contamination and infection of the treated pigs 
by the adjacent control pigs following end of 
antibiotic therapy could have played a factor in 
the resulting second diarrheal phase. The 
immune response to diarrheal disease in the 
control animals was not effective in preventing 
the second diarrheal phase. 
The microbiological data was interesting in 
this trial. Rotavirus recovery was much lower in 
the treated pigs. The sensitivity of the electron 
microscopy detection is 105 particles/ml. The 
decreased rotavirus detection indicates lower 
replication of rotavirus in the treated pigs. E.coli 
detection was also lower with no organisms 
detected 3 days PC indicating that the treatment 
reduced the load of E.coli. Subsequently the 
levels of E.coli recovery during the second 
diarrheal phase were similar between the two 
groups. The challenge 0111 serotype could not 
be recovered after the initial infection. We have 
no explanation for these phenomena. 
The serological data in this experiment was 
not useful. There was a single control pig that 
responded to the M. hyopneumoniae vaccine. 
The vaccine used in this trial (M. hyopneumonia 
vaccine, Oxford Laboratories) was a different 
product from that used in the previous trial3 
(Respisure, Pfizer). The manufacturer of the 
vaccine was the same company that performed 
the M. hyopneumoniae ELISA test. Both the 
efficacy of the vaccine and the sensitivity of the 
ELISA testing method are questionable and 
neither the vaccine nor the tests are available. 
The immunological data was similar to that 
seen in our two previous studies 2·3•6• There was 
a decreased T cell response indicating a lower 
inflammatory response. This decreased 
inflammatory response has a sparing effect that 
allows increased growth in the treated pigs. The 
antibody capacity and production of the treated 
animals as measured by B cell mitogen activity 
and forced immunoglobulin should allow them to 
respond to a challenge. 
Conclusions 
These results indicate an increase in daily 
gain and feed efficiency with pigs treated with an 
oral antibiotic regiment. The E.co/i-rotavirus 
challenge model indicated an advantage to the 
treated pigs with a lower fever response 
increased clearance of E.coli and rotavirus and 
decreased T cell activation. These decreased 
physiological and immunological responses and 
higher pathogen clearance are all factors that 
could result in the increased production 
parameters in the treatment group. 
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TABLE 1". WEANING PERFORMANCE (STARTER PHASE-DAYS 17-61, 10-46 
LBS. 
Daily gain, lbs. 
Daily feed. lbs. 
Feed/gain 
Control 
0.756 
1.418 
1.900 
Treatment 
0.827 
1.440 
1.742 
P value 
0.124 
0.542 
0.079 
TABLE 1b. PERFORMANCE (GROWER PHASE-DAYS 62-105, 46-118 LBS.) 
Daily gain, lbs. 
Daily feed lbs. 
Feed/gain 
Control 
1.647 
4.083 
2.489 
Treatment 
1.689 
4.248 
2.511 
Pvalue 
0.465 
0.258 
0.717 
TABLE 1°. PERFORMANCE (FINISHING PHASE-DAYS 106-160, 118-234 LBS.) 
Daily gain, lbs. 
Daily feed. lbs. 
Feed/gain 
2.052 
6.356 
3.116 
Control 
2.026 
6.377 
3.153 
Treatment 
0.762 
0.911 
0.595 
P value 
TABLE 1d. OVERALL PERFORMANCE (DAYS 17-160, 10-234 LBS.) 
Daily gain, lbs. 
Daily feed. lbs. 
Feed/gain 
Control 
1.529 
4.154 
2.730 
Treatment 
1.554 
4.222 
2.717 
TABLE 1°. CARCASS PERFORMANCE (234 LBS.) 
10th Rib Fat Thickness, in. 
Loin Eye Area, sg. in. 
Control 
0.849 
5.175 
Treatment 
0.849 
5.076 
TABLE 2. ROTAVIRUS DETECTION IN PIGS 
Days Post Challenge 
Daya Day3 Day10 Day 16 Day24 
Control neg. pas. pas. pas. .neg. 
Treated neg. pas. neg. neg. neg. 
pas-virus ·detected in fecal samples 
neg-no virus was detected in fecal samples 
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Day28 
neg. 
neg. 
P value 
0.570 
0.435 
0.793 
P value 
0.999 
0.405 
Day35 
neg. 
neg. 
DayO 
Control 0 
Treated 0.1 
0-no hemolytic E.coli 
1-few hemolytic E.coli 
2-moderate hemolytic E.coli 
3-many hemolytic E.coli 
TABLE 3. 
Day3 
1.1 
0 
E.coli DETECTION IN PIGS 
Days Post Challenge 
Day 10 Day 16 Day24 Day28 Day35 
1.3 1.1 2.3 1.3 0.1 
0.9 1.6 2.0 0 0.4 
TABLE 4. SEROLOGICAL RESPONSE (LOG10) TO Mycoplasma hyopneumoniae 
(NUMBER OF PIGS SEROPOSITIVE/TOTAL NUMBER OF PIGS TESTED) 
Days of age 
Day10 
Day56 
Treatment 
0 (0/10) 
0 (0/10) 
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Control 
0.77±1.25 (3/10) 
0.32+1.01 (1/10) 
